cyrilzakka/clinical-trials huggingface dataset:
An Integrative Model for Palliative Care in End-Stage Liver Disease

The purpose of this research study is to understand the impact of palliative care in ESLD on quality of life, emergency room or hospital visits, and on care provider burden, and to work to develop the best way to provide palliative care in ESLD.

Patients with end-stage liver disease (ESLD) have multiple symptoms that impact their quality of life and result in more emergency room and hospital visits. Palliative care is a medical model that can help alleviate pain and suffering and reduce need for urgent medical care and can do so while continuing other appropriate medical care. While palliative care consults are used in those with ESLD, despite the pain and suffering that accompanies ESLD, palliative care is often used too little and too late.

Eligibility Criteria:
Inclusion Criteria:

Primary participant:

* admission for decompensated cirrhosis, age ≥ 18
* willingness to sign consent
* able to read and understand English
* presence of decompensated cirrhosis with portal hypertension (jaundice, ascites, HE, hepatohydrothorax, AKI, HRS and/or variceal bleeding) or HCC

Caregiver:

* identified as the primary caregiver of the participant
* age ≥ 18
* willingness to sign consent
* able to read and understand English

Exclusion Criteria:

Primary participant:

* prior liver transplant
* lack of capacity to provide informed consent (in the judgement of the investigator)
* already in receipt of palliative or hospice care
* those who are likely to receive a LT during the index admission

Caregiver:

• none
Stretching Isquiotibials in Water and on Land in Healthy Adutls

Comparison of therapeutic intervention to gain range of motion at the hip joint within therapeutic in water and on land. Stretching is a therapeutic maneuver used to increase the length of shortened soft tissue structures and thereby gain range of motion; for that, innumerable procedures within Physiotherapy use it for the benefit of patients. The work in question is justified by the need to seek the means that can promote a better performance in the application of the stretching procedure, called Proprioceptive Neuromuscular Facilitation, in a universe of pre-selected volunteers. It is a relevant and feasible study, hoping that its results may benefit future patients, with better results and faster responses. What is the medium that leads to better results in a program using the proprioceptive neuromuscular facilitation technique? Hypotheses: a - Probably the heated aquatic environment, in a range of 32 ° to 36 ° C, will promote a better result, since the heat increases the collagen's distensibility. b - Perhaps the heat, by increasing the excitability threshold of nerve fibers, triggers the "protective reflex" later, which may promote a more vigorous elongation without the protective response. c - Possibly the relaxation promoted in the aquatic environment, could influence the gains obtained in the swimming pool.

Comparison of therapeutic intervention to gain range of motion at the hip joint within therapeutic in water and on land.

Eligibility Criteria:
Inclusion Criteria:

* age between 18 and 60 years;
* sedentary and who did not perform physiotherapy and physical activity in the last three months;
* clinical and cognitive conditions for swimming pool activities and aerobic exercise; who have not undergone highly complex surgical procedures in the last six months;
* to be able of walking without help equipment and without musculoskeletal or skeletal diseases;
* without contraindications to the practice of exercises; such as: urinary and / or fecal incontinence and dermatological diseases;
* below obesity II with BMI \<40.

Exclusion Criteria:

* if they have up to three consecutive fouls during the hydrogymnastics period;
* if they present any adverse effects, such as: allergy or any dermatitis;
* unable to continue the study due to change of address or hospitalization.
Comparing Pain Relief Between Exparel® Injection vs. On-Q Catheter as the Postsurgical Analgesia Following Total Knee Arthroplasty (TKA)

The goal of this research project is to evaluate the effectiveness of a novel treatment to control pain after Total Knee Arthroplasty (TKA). The proposed approach to manage pain and eliminate risks associated with catheters is the use of Exparel injection into the joint at the time of surgery.


Eligibility Criteria:
Inclusion Criteria:

1. Adults scheduled to undergo primary total knee replacement
2. Willing and able to provide informed consent
Title: Urinary Oxytocin Levels in Children Receiving Animal-Assisted Therapy

There has been growing interest in animal-assisted therapy (AAT) in recent decades due to increasing reports indicating its health benefits for adult patients. These benefits are partly attributed to changes, usually increased levels of the neuropeptide oxytocin.

Aim: To investigate changes in oxytocin levels in hospitalized children during animal-assisted therapy sessions with a certified hospital dog.

Method: Urine samples were collected from 35 hospitalized children (3-17 years) before and after each participant had a session with the hospital dog. Oxytocin levels were analysed with an acetylcholinesterase (AChE) competitive enzyme-linked immunosorbent assay (ELISA). Creatinine levels were measured to determine the subject's fluid intake and then divided by the hormonal concentration (uOT pg/mg).


Eligibility Criteria:
Inclusion Criteria:

* Hospitalized children

Exclusion Criteria:

* Multiresistent bacteria
* Immunosuppressed
* Large burns
Alpha Lipoic Acid for Burning Mouth

Discussion and evaluation of patients with sore and burning mouth to determine whether alpha lipoic acid is helpful in managing their symptoms.


Eligibility Criteria:
Patients seen in the Department of Dermatology with diagnosis of burning mouth syndrome between 2000 and 2005
Single Incision Transvaginal Mesh in Treatment of Posterior Vaginal Wall Prolapse

Definition: To find out complications, objective and subjective outcomes of patients with symptomatic posterior vaginal wall prolapse undergoing posterior mesh operation in nine Finnish hospitals during September 2010 and August 2013. The study hypothesis is that complications are acceptable and both objective and subjective outcomes are satisfying.

The aim of this study is to investigate the safety and efficacy of Elevate®Posterior transvaginal mesh kit. Secondly the investigators want to evaluate the effect of this surgical method on non-affected anterior vaginal compartment as well as patients' outcome.

This prospective multicenter national study include patients (n=111) with symptomatic posterior vaginal wall with or without apical prolapse with stage II or more. Patients were recruited at four university hospitals and five central hospitals in Finland between September 2010 and August 2013. The study protocol was approved by the Ethics Committees in participating hospitals and all attending patients gave written consent after oral and written counseling. Baseline evaluation include standardized gynecological examination in supine position using the POP-Q system. Detailed information on patients' characteristics and medical history is gathered, focusing on especially gynecological issues. Patients fill in Pelvic Floor Distress Inventory (PFDI-20) and Pelvic organ prolapse/urinary Incontinence Sexual Questionnaire (PISQ-12).

The operations are performed by qualified surgeons (n=9) familiar with transvaginal mesh surgery. Intraoperative data is collected and immediate postoperative problems are registered.

The first follow-up visit take place at three months postoperatively. Gynecological examination with POP-Q measurements are performed and complications documented. As preoperatively, PFDI-20 and PISQ-12 questionnaires are filled in by the patients.

The second visit take place at one year postoperatively. Gynecological examination with POP-Q measurements are performed and possible late complications documented. PFDI-20 and PISQ-12 questionnaires are filled in again by the patients.

Eligibility Criteria:
Inclusion Criteria:

* patients with symptomatic posterior vaginal wall with or without apical prolapse with stage II or more

Exclusion Criteria:

* concomitant surgery, immunosuppressive treatment of any kind, previous or forthcoming bowel operation with low anastomosis creation and previous vaginal radiation therapy
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine

The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.


Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Concomitant medications for the treatment of complications of AIDS.
* CAUTION:
* Concomitant use of ddI with the following drugs must be done with extreme caution:
* Other nucleosides (e.g., ganciclovir).
* Drugs with toxicities similar to those observed with ddI (e.g., phenytoin).
* Drugs with significant pancreatic toxicities, including many drugs used for treatment of major opportunistic infections.
* Use of Sulfonamides or intravenous pentamidine for treatment of acute Pneumocystis carinii pneumonia (PCP) requires discontinuation of ddI for a week following treatment of PCP.
* Caution should also be exercised with patients having intractable diarrhea or patients following a low sodium diet.

Patients must have the following:

- Diagnosis of AIDS. Demonstrated either significant deterioration despite parenteral dosing with zidovudine (AZT) or significant intolerance to AZT.

Signed informed consent by parent or legal guardian. Evaluations every 7-14 days while taking ddI for the first 4 months. Monthly follow-up is required thereafter.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Acute pancreatitis or any history of pancreatitis.
* Seizures or a history of seizure disorder.
* Grade I or greater peripheral neuropathy.
* Preexisting cardiomyopathy.

Concurrent Medication:

Excluded:

* Zidovudine (AZT).
* Chemotherapy with cytotoxic agents.
* AVOID:
* Those agents that may cause pancreatitis such as:
* Pentamidine.
* Sulfonamides.
* Antituberculosis drugs.
* Cimetidine.
* Ranitidine.
* Corticosteroids.
* NOTE the cautionary statement in Patient Inclusion Concurrent Medication.

Patients with the following are excluded:

* Acute pancreatitis or any history of pancreatitis.
* Seizures or a history of seizure disorder.
* Grade I or greater peripheral neuropathy.
* Preexisting cardiomyopathy.

Prior Medication:

Excluded within 15 days of study entry:

* Any anti-retroviral except zidovudine (AZT).

Required:

* Zidovudine (AZT).
Compliance of Blood Pressure and Lipid in Hypertensive Patients Under the Management of Hospitals at Different Levels

This is a multi-center, prospective cohort study that collects only diagnostic and therapeutic data in subjects but does not interfere with treatment.

The study aims to assess blood pressure and lipid levels, the use of lipid-lowering and antihypertensive drugs, and treatment compliance and adverse events in hypertensive outpatients of 30 hospitals of different levels, following them up for 1 and 3 months after treatment, respectively. The study would reveal the compliance of blood pressure and lipid levels in hypertensive patients under management of hospitals at different levels, and analyze factors affecting blood pressure or lipid levels associated with treatment compliance. Therefore, the study would provide clinical data from the real world for future prevention and control of CVD in China.

Eligibility Criteria:
Inclusion Criteria:

Patients meeting the following criteria will be included:

1. Age ≥18 years, male or female;
2. Agreement for blood pressure and lipid testing;
3. Initial diagnosis of primary hypertension, with blood pressure conforming to the diagnostic criteria of the 2018 Guidelines for the Prevention and Treatment of Hypertension in China \[14\] (with no antihypertensive drugs, SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg after three tests performed on different days); or a history of primary hypertension but incompliant blood pressure;
4. Willingness to participate in the study and signing of informed consent.

Exclusion Criteria:

* Patients meeting the following criteria will be excluded:

  1. Involvement in an interventional clinical research;
  2. Pregnancy or lactation in women;
  3. Complication with malignant tumors;
  4. Diagnosis of non-primary hypertension by researchers;
  5. Impaired cognitive ability;
  6. Researchers believing that the patients have other conditions not suitable for the study.
Mhealth Social Support for People at Risk of Metabolic Syndrome

This trial is to examine the feasibility, acceptability, and preliminary effect of a mHealth social support program on lifestyle modifications among people at risk of metabolic syndrome in Hong Kong at 3- and 6-month follow-ups.

Metabolic syndrome is a cluster of unhealthy conditions that affects more than 1 billion people in the world. Lifestyle modifications can reduce the risk to develop metabolic syndrome, while the report showed that over 95% of people in Hong Kong did not practice healthy lifestyle. This trial is to examine the feasibility, acceptability, and preliminary effect of a mHealth social support program on lifestyle modifications among people at risk of metabolic syndrome in Hong Kong. Eighty eligible participants will be recruited from community centers and be randomized into intervention group or control group. Participants in the control group will receive a mobile app with limited function, while those in the intervention group will receive a theory-guided mhealth social support program. Data will be collected at baseline, 3 months, and 6 months on the outcomes of feasibility, acceptability, and lifestyle modifications. Data will be analyzed using a generalized estimating equation based on the intention-to-treat principle. The findings of this study will provide valuable information for a full randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

1. Chinese adults aged ≥ 45 years
2. With central obesity according to IDF criteria
3. Being treated of hypertension, dyslipidemia, or diabetes
4. Able to give informed consent
5. Attain at least 6 years of formal education
6. Have a smartphone with internet connection and able to use WhatsApp

Exclusion Criteria:

1. Concurrently participating in another clinical trial, lifestyle/dietary intervention, or weight control program
2. Known history of psychiatric disorders
Role of C-Reactive Protein /Albumin Ratio in Evaluation of Disease Activity in Patients With Inflammatory Bowel Disease

Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.

Inflammatory bowel disease (IBD) is defined as a life long chronic inflammatory disease affecting the gastrointestinal tract resulting from the interaction of environmental and genetic elements, has been a global healthcare problem with a steadily increasing incide IBD is mainly composed of two different bowel-relapsing disorders, including Crohn's disease (CD) and ulcerative colitis (UC).

Early detection of the disease activity of IBD is of great significance for the treatment of this disease, which can effectively prevent complications and therefore improve prognosis as well as quality of life. In current clinical practice, commonly used noninvasive biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), are considered to be important for both early diagnosis and accurate monitoring of the disease activity in IBD patients.

The C-reactive protein/albumin ratio (CAR) is indicative of the balance between inflammation and nutritional status, making it an excellent marker for assessing disease activity in patients The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity inde (CDAI).

Eligibility Criteria:
Inclusion Criteria:

* patients with IBD which included Crohn disease and Ulcertive colitis patients above age 18 years old.

Exclusion Criteria:

* concurrent infections, liver cirrhosis, hematological diseases, heart failure, malignancies, autoimmune diseases, or congenital or acquired immunodeficiencies
Effect Evaluation of Early Exercise Training After Myocardial Infarction

The aim of the study is to evaluate the effect of early onset of exercise training (ET) after myocardial infarction (MI) in a randomized controlled trial. Usual care is to wait 4-6 weeks after onset of MI, and our hypotheses are that early ET will prevent a fall in VO2peak and contribute to better quality of life.

Exercise training is well documented as effective treatment for myocardial infarction(MI) patients. However, the long time effect of early onset is more unclear, and it is needed to provide knowledge about to which extend early onset of ET contribute to reduce risk factors, increase oxygen consumption and influence on quality of life.

A RCT is conducted, 60 persons with recently MI is invited to participate. The subjects participating is hospitalised in St. Olavs Hospital. The participants are randomised to either a training group or a control group. The training group will be offered hospital out-patient group exercise training of moderate intensity twice a week for four weeks. The training is leaded by a physiotherapist. The control group will wait four weeks before both groups continue ET twice a week for 12 weeks (high intensity training).

Eligibility Criteria:
Inclusion Criteria:

* Myocardiac infarction, 2 weeks ago
* over 18 years
* able to participate i exercise groups

Exclusion Criteria:

* unstable angina
* heart failure
* failure to reach a maximal pretest
* drug abuse
Second Bowel Preparation for Colonoscopy Failure

Colonoscopy is a basic but important tool to diagnose and treat lesions of the colon. Proper colon cleansing is essential for colonoscopy to be performed with a good quality. Inadequate bowel preparation leads to longer colonoscopic insertion time and patient discomfort, as well as inadequate diagnostic yield of colonic lesions. Frequency of colonoscopy failure due to bad bowel preparation is reported to be 0.3% to 6.5 percent, and the rate increases with liver cirrhosis, constipation, dementia, stroke, or administration of tricyclic antidepressants. In case of colonoscopy failure due to bad bowel preparation, the second colonoscopy can be performed with either adding a colon cleansing solution immediately, or it can be performed after a few days with colon cleansing agent together with prokinetics. These different kinds of bowel preparations after first colonoscopy failure have not been compared.


Eligibility Criteria:
Inclusion Criteria:

* First colonoscopy failure due to inadequate bowel preparation

Exclusion Criteria:

* younger than 18 years old
* presence of inflammatory bowel disease
* pregnant
* lactating
* refusal
Effectiveness of the Hippotherapy Simulator in Children and Adolescents with Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disease that affects many organs and systems, especially respiratory system problems due to lung damage. Patients often have difficulty in removing the sticky and viscous secretion that accumulates in the respiratory tract, and the risk of mortality increases with the development of respiratory failure. In patients with CF, exercise capacity, peripheral muscle strength, core endurance, flexibility, postural stability, physical activity level, and quality of life also decrease secondarily. Recently published guidelines recommend respiratory physiotherapy for coping with CF-related symptoms and recommend referral of patients to physical activity and exercise.

Hippotherapy simulator is a mechanical exercise tool that imitates the walking movement of a real horse and is used to increase physical fitness parameters.

This study aims to show the effects of exercises performed with a hippotherapy simulator in addition to respiratory physiotherapy on physical fitness, sputum production, physical activity and quality of life of children with CF.


Eligibility Criteria:
Inclusion Criteria:

* Be in the 8-14 age range
* To be diagnosed with cystic fibrosis according to the American Cystic Fibrosis Association consensus report criteria
* Having mild (FEV1 ≥ 70% predictive) lung disease according to the disease severity classification in the annual report of the American Cystic Fibrosis Society
* To be able to produce phlegm

Exclusion Criteria:

* Contracture or deformity,
* History of diagnosed orthopedic problems affecting mobility or musculoskeletal surgery
* History of previous lung or liver transplant
* Have diagnosed vision, hearing, vestibular or neurological problems that may affect balance,
* History of hospitalization in the last 1 month
* Patients who have participated in any exercise training program in the last 6 months
A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer

This study evaluates a nutritional supplement in the treatment of pancreatic cancer in adults. Half of the participants will receive the nutritional supplement, while the other half will receive a placebo.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer scheduled for resection of the tumor.
* Patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer, subsequently found to have biliary or ampullary cancer upon full pathological review, scheduled for resection of the tumor.
* Patients with a CT image, which includes scans of the 3rd lumbar region, taken within 45 days before tumor resection surgery.
* Ability to maintain oral intake.
* Ability to give written, informed consent.

Exclusion Criteria:

* Patients found to have a diagnosis other than pancreatic, biliary, or ampullary cancer upon full pathological review.
* Patients with a benign tumor.
* Patients taking drugs that modify muscle metabolism.
* Patients with uncontrolled jaundice.
* A compliance rate of \<80%, excluding compliance during recovery from tumor resection surgery while in the hospital.
* Patients currently taking the nutritional supplement being investigated in this study.
* Patients in the placebo group who have plasma levels of the nutritional supplement components within the range of the nutritional supplement group at study time points when plasma levels of the nutritional supplement components are significantly higher in the nutritional supplement group versus the placebo group.
* Inadequate specimens.
* Known allergy to gelatin or glycerin.